Thursday, August 16, 2007

Health Canada reviews osteoarthritis drug after Australia concerns

From the Globe and Mail:
Health Canada says it is reviewing safety information for the drug Prexige (lumiracoxib) after Australian health authorities withdrew the drug from that market due to reports of serious liver problems, including two deaths, in eight people who had taken the drug.

Health Canada says it has asked for information about adverse events involving the liver from the drug's manufacturer, Novartis, and will update recommendations to the public and health care professionals if necessary.

Prexige is a member of the troubled cox-2 inhibitor class of drugs, a class which includes the now withdrawn drug Vioxx. Prexige is used for treatment of osteoarthritis in adults.

Australia's Therapeutic Goods Administration recently withdrew market authorization for Prexige due to eight reports of serious liver adverse events linked to the drug in that country, including two deaths and two liver transplants. ...more

No comments: